Vaccinex presents data on anti-semaphorin 4D monoclonal antibody technology
Vaccinex announced it presented both a poster and a podium session regarding its anti-semaphorin 4D monoclonal antibody technology, which serves as the basis of its investigational drug pepinemab. The data were presented at the International Cancer Immunotherapy Conference, or CIC. The data outlined results from several preclinical studies of the anti-SEMA4D MAb as both a single agent and in combination with various immunotherapy agents. The data demonstrated the blockade of semaphorin 4D allowed dendritic and cytotoxic T cells to migrate into the tumor, while reversing myeloid-derived immunosuppression. Further, the anti-SEMA4D MAb enhanced the activity of co-administered immunotherapy in mouse melanoma, head and neck, and colon carcinoma models. Specifically, the company's MAb plus anti-CTLA-4 resulted in 100 percent survival and 90 percent tumor rejection in head and neck cancer models. In addition, anti-SEMA4D combined with HDAC inhibitor entinostat resulted in maximal tumor growth delay and 90% complete response in Colon26 tumor models. The design of ongoing pepinemab combination immunotherapy clinical trials was also presented.